

Special Issue

Molecular Therapy Targets of Uterine and Ovarian Cancer

Message from the Guest Editors

Uterine and ovarian cancers continue to pose major clinical challenges, but recent years have ushered in unprecedented progress in the molecular characterization and targeted treatment of these malignancies. Nowhere has this been more transformative than in endometrial cancer, where the integration of molecular classification (TCGA/ProMisE) has reshaped risk stratification and therapeutic decision-making. The emergence of immune checkpoint inhibitors for dMMR/MSI-H tumors, novel HER2-directed therapies for serous subtypes, and expanding combinations of endocrine agents with CDK4/6 inhibitors illustrate the rapid clinical translation of molecular discoveries. In this Special Issue, submissions may address—among others—the following areas: molecular biomarkers guiding immunotherapy; HER2 and other receptor-targeted therapies; genomic and epigenomic mechanisms of drug resistance; multi-omics approaches; novel antibody-drug conjugates; tumor microenvironment and immunomodulation; synthetic lethality strategies; and innovative delivery systems for targeted therapeutics.

Guest Editors

Dr. Salvatore Lopez

Ginecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II",
Bari, Italy

Dr. Fabian Kraus

Department of Obstetrics and Gynecology, Comprehensive Cancer
Center Munich, University Hospital, LMU Munich, Marchioninstr. 15,
81377 Munich, Germany

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/268336

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)